Background & Aims: No specific microbiome in patients with hepatocellular carcinoma (HCC) has been reported to date. Our aim was to compare gut microbiome found in cirrhotic patients with and without HCC.
Introduction.
Increasing interest has been focused during the last years regarding microbiome and human diseases including cirrhosis, alcoholic liver disease, fatty liver and fibrosis progression. Changes in gut microbiome have been observed with progression of liver disease [1] [2] [3] [4] including a reduced abundance of taxa considered benign, such as Lachnospiraceae, Ruminococcaceae and Clostridialies and a higher abundance of Enterobacteriaceae and Bacteriodaceae 2 . This gut microbiome profile remains stable unless a decompensation of cirrhosis appears with a relative increase in Enterobacteriaceae and Bacteriodaceae 2, 5 .
A renewed novel research has focused on microbiome and cancer development.
However, scarce data has been written regarding microbiome and hepatocellular carcinoma (HCC). In patients with cirrhosis, there is an annual risk rate between 1 to 6% of developing HCC [6] [7] [8] . Previous studies showed that the severity of liver disease and chronic inflamation 9 are predictors for development of this tumor 10, 11 . These changes have been linked to an inflammatory pro-oncogenic microenvironment from the intestine to the liver in murine models 12 .
Inflamatory signals derived from a change in intestinal microbioma has been proposed as a novel carcinogenic mechanism [12] [13] [14] . This gut-liver axis may also become a potentially preventive therapeutic target 15, 16 . The aim of this study was to evaluate the gut microbiome found in patients with HCC and to understand whether or not there is a specific gut microbiome profile among cirrhotic patients with HCC when compared to those without HCC.
Patients and Methods

Study design, setting and participating centers
This observational case-control study was nested on a prospective longitudinal cohort of patients with cirrhosis who were followed-up in our liver unit at Austral University Hospital, School of Medicine; in colaboration with HERITAS (Rosario), CONICET and the National Academy of Medicine. This study was carried out between December 2015 and October 2016 in accordance with international recommendations for observational studies 17 .
Eligibility criteria
A consecutive non-probability sampling of adult subjects (>17 years old) with clinical or histological diagnosis of cirrhosis, functional status Child Pugh class A or B was included. Clinical or histological diagnosis of cirrhosis was done according to international consensus guidelines 18 . Exclusion criteria consisted of any of the following: a) Previous liver transplant, b) patient under any immunosuppressive treatment, c) prior or current treatment with any pre-or probiotic, d) active alcoholism (cessation of alcohol intake at least 3 months prior to study entry), e) past or present history of neoplasms, f) any major surgery or severe traumatic injury within 28 days prior to inclusion, g) active infection grade >2, according to the NCI CTCAE criteria, version 4.0 19 , h) infection with human immunodeficient virus (HIV), i) any antibiotic treatment should have been completed one month prior to the inclusion, excluding primary or secondary prophylaxis for bacterial infections in cirrhosis, j) diarrhea secondary to any commensal, including Clostridium difficile diarrhea within 6 months prior to the inclusion of the subject in the study, k) any malabsorption disorder, celiac disease or inflammatory bowel disease including ulcerative colitis and Crohn's disease.
Selection of cases and controls
Cases were defined as those patients meeting the above eligibility criteria and with imaging or histological diagnosis of HCC. Imaging HCC diagnosis was performed with a tri-phase dynamic study, either Computerized Axial Tomography (CT) or Magnetic Resonance Imaging (MRI) as recommended by international guidelines 20, 21 .
All cases were allowed to have a history of HCC treatment, excluding liver transplantation. They should have at least one active HCC nodule 22 at time of fecal stool sample collection. Images were centrally reevaluated by a single observer, blinded to clinical and exposure variables.
Every case was matched with one control without HCC (wo-HCC) in a 1:1 ratio according to age, gender, etiology of liver disease, Child Pugh score and presence of clinically significant portal hypertension. Exclusion of HCC in all controls was done with either CT or MRI scans during the screening period. Selection process of cases and controls was prior to evaluation of microbiome on stool samples, and was blinded from results of gut microbiome.
Healthy controls
In addition, we studied a gut microbiome dataset of a total of 25 matching healthy controls. These subjects were included in a previous epidemiological microbiome research from Rosario, Argentina 22 . This dataset was validated using the Illumina MiSeq technology as described below exclusively for this work.
Exposure variables: definition and meassurement.
The following measurements were recorded at baseline in each subject enrolled:
. Demographic data: age, weight and height, concomitant medications including use of lactulose, rifaximin or norfloxacin.
. Laboratory including red and white blood cells count, platelets, liver function tests, urea, creatinine, plasma electrolytes, prothrombin time, INR (International Normatized Ratio) and serum alpha-fetoprotein (AFP). These blood tests were measured in the same day or the day after fecal stool sample collection in all subjects blinded from clinical variables and microbiome results.
. Clinical variables: complete physical examination and past medical history, Child Pugh Score and presence or past history of clinically significant portal hypertension was evaluated during the screening period and revaluated at the same day of fecal sample stool collection. The latter included presence of ascites, hepatic encephalopathy (HE; West Haven grade criteria) 23 and presence of esophageal or gastric varices. The degree of ascites was classified as mild, moderate or severe according to ultrasonographic or physical examination.
. Tumor characteristics: Subjects with HCC diagnosis were staged according to Barcelona Clinic Liver Cancer staging (BCLC) 20, 21, 24 at study entry. Type of previous tumor treatment was registered: trans-arterial chemoembolization (TACE), radiofrequency ablation (RFA), percutaneous ethanol injection (PEI) and liver resection (LR).
Fecal stool samples collection, DNA extraction and sequencing.
Fecal samples were obtained noninvasively either at home or in the hospital, in a plastic collection kit at any time during the day. All samples were stored at -70°C.
Samples obtained at patient's home, were maintained for 24hs at 4 ºC, until they were taken to the hospital and stored at -70 ºC. 
Sequence data pre-processing, classification and taxonomic assignment
Amplicon sequencing produced 11639500 raw paired-end (PE) reads. We followed the 16S SOP described in Microbiome Helper 27 . FastQC (v0.11.5) was used to analyze the raw data quality of PE reads. Paired-end reads were stitched together using PEAR (v0.9.10). Stitched reads were filtered by quality and length, using a quality score cut-off of Q30 (phred quality score) over 90% of bases and a minimum length of 400bp. Concatenated and filtered fastq sequences were converted to fasta format and we removed sequences that contain 'N'. Potential chimeras were checked using the UCHIME algorithm, and then the chimeric sequences were removed.
The remaining sequences were clustered to operational taxonomic units (OTUs) at 97% similarity level with a open reference strategy implemented in QIIME (v1.91), using SortMeRNA for the reference picking against the SILVA (v119) database and SUMACLUST for de novo OTU picking.
Study end-points
The objective of this study was to compare gut microbiome profile in patients with cirrhosis with and without HCC, in order to identify a specific profile of microbiome potentially associated with the risk of developing liver cancer.
Potential biases and confounding variables
In order to anticipate and avoid selection bias regarding HCC-cases and wo-HCC, subjects were followed and treated under the same standards of care and were selected from a cohort of patients prospectively followed at Austral University Hospital by investigators who were blinded to gut microbiome results. Acceptances and declines to participate in this study were recorded. Selection bias was avoided, excluding HCC diagnosis with a CT or MRI scan in wo-HCC controls.
Statistical analysis
A statistical two-tailed value, α type I error or 5% (p value <0.05) was considered. represented by two dimensional principal coordinates analysis (PCoA) plots. The R package phyloseq (https://github.com/joey711/phyloseq) was used to import and plot data, and the package DESeq2 was used to perform differential abundance estimates.
The evaluation of beta diversity between cases (HCC) and controls (wo HCC) were also determined using a principal fitted components for dimension reduction in regression as it was used to analyze microbiome data 25 .
Ethical considerations.
This study protocol has been developed according to national standards for ethical, legal and regulatory requirements established in the 6677/10 ANMAT disposition, international ethical standards according the 2008 Helsinki Declaration and its amendments from the Nuremberg code, universal declaration on the human genome and human rights adopted by the General Conference of UNESCO 1997, as well as GCP standards ("Good Clinical Practice").
Results.
Participating Patients characteristics
From a total of 407 patients who were prospectively followed and entered in the prescreening study period, 72 patients with HCC and 190 without HCC were selected as potential cases and controls. Overall, 25 cases and 25 controls (wo-HCC) were well matched according to those variables previously described and were included in the final assessement of gut microbiome (Figure 1) . A subgroup of 25 healthy individuals were also enrolled, matched according to gender in a 1:1 ratio 26 . Baseline patient characteristics are shown on Table 1 . Considering severity of liver disease, most of the patients were Child Pugh A (74%), only 10% had ascites and 8% had presence of HE.
Cases and controls: Clinical and tumor variables.
In patients with HCC the mean number of intrahepatic nodules were 2. Table 2 shows baseline clinical and laboratory variables comparing cases and controls. There were no significant differences in any clinical variable. The use of rifaximin, norfloxacin or lactulose was not significantly different between cases and controls.
Alpha and beta diversity in the gut microbiome of Cases, Controls and Healthy subjects
Cases and controls (wo-HCC) datasets of the gut microbiome were compared to a gut microbiome dataset of healthy subjects from the city of Rosario (Argentina). The alpha diversity index indicated that healthy controls showed the most diverse dataset of gut microbiome compared to cases and controls ( Figure 2 ). On the contrary, wo-HCC dataset consistently and significantly showed the less diverse dataset of gut microbiome. The HCC dataset was less diverse than healthy controls but still more diverse than the wo-HCC dataset.
The beta diversity analysis performed using a log-data transformation in a Bray-Curtis PCoA showed that the cases and wo-HCC groups were clearly separated from the healthy control population ( Figure 3A) . To gain in-depth insight of cases and wo-HCC group, we performed a principal fitted components analysis with dimension reduction that showed a more precise and clear separation of the gut microbiome datasets between groups ( Figure 3B ). However, there were still a group of patients with no difference in beta diversity analysis of gut microbiome between cases and controls.
Taxonomic distribution analysis of the gut microbiome
Taxonomic abundance at Phylum, Family and Genus levels were investigated for cases, wo-HCC and healthy groups. Differences in the relative abundance of taxa were evident at the levels of Family and Genus among the three groups. Of note is the expansion of Bacteroidaceae and reduction of Prevotellaceae in the HCC group that, in turn, is reflected at the genus level in Bacteriodes and Prevotella. Consequently, the bacteriodes/prevotella ratio is greater in HCC than in the two other groups (Figure 4 A-C).
To further investigate which taxa is accounting for the observed differences in alpha and beta diversity of the gut microbiome in the HCC group, we performed a differential abundance analysis using phyloseq and DEseq2 ( Figure 5 ). Several genera showed interesting correlations such as Fusobacterium, Prevotella, Streptoccocus,
S24-7 (Phylum Bacteroidetes) and an unknown genus (phylum Firmicutes, family
Leuconostocaceae), all of which were decreased 2 to 5-fold in HCC group. On the other hand, Haemophilus, Eggerthella, Bifidobacterium, Butyricimonas, Christensella, Odoribacter, an unknown genus (phylum Tenericutes) and an unknown genus (phylum Firmicutes, family Erysipelotrichaceae) were all elevated by 2 to 3fold in HCC group (Figure 4) . Each genus in Figure 4 is the result of the mean abundance of several OTUs contained in that genus and only those with significant differential abundances with an adjusted P value of 0.05 are shown. Interestingly, all the changes in abundance in Figure 4 correlated with an increase in the predicted metabolism of NOD-like receptor (NLR) signaling pathway in the HCC group (Supplemenatary Figure 2) . The NLR signaling pathway was previously reported to be involved in inflammatory and autoinflammatory processes 14 .
Discussion
To the best of our knowledge, this is the first observational study to identify a specific gut microbiome among patients with cirrhosis with and without HCC. Patients with HCC had lower quantities of genus Prevotella, Fusobacterium and family Leuconostocaccaceae among others and an elevated proportion of genus Bifidobacterium, Eggerthella, Haemophilus, family Erysipelotrichaceae and phylum Tenericutes when compared to controls without HCC. This pattern has been associated with an inflammatory milieu with increased activation of NLR signalling pathways.
Interestingly, in our study the HCC group showed a more diverse gut microbiome than the wo-HCC group but still less diverse than a healthy population control. This observation could be relevant in the context of disease development and progression suggesting an expansion of certain families or genera of microbes in the tumor microenvironment with an inflammatory milieu. These findings suggest a tumor specific expansion of microbiota 27 .
It is interesting to note that some families in the phylum Firmicutes were either significantly decreased or elevated in HCC cases versus controls wo-HCC.
Hepatocellular carcinoma is a pro-inflamatory cancer as previously mentioned 15 . We observed a 3-fold increased of Erysipelotrichaceae in HCC patients. This family of firmicutes has been implicated in inflammation related to gastrointestinal diseases and in tumor development such as colorectal cancer 28 . Besides, the relative abundance of Erysipelotrichi positively correlated with tumor necrosis factor alpha (TNF) levels in a patients with HIV infection 29 . Further evidence showed that the abundance of Erysipelotrichi were also positively associated with changes in fatty liver in female subjects who were placed on diets in which choline levels were manipulated 30 .
On the other hand, family Leuconostocaceae, a main producer of acetate and lactate, was decreased by 5-fold in HCC cases versus controls wo-HCC, as also observed in ulcerative colitis 31 . It is important to mention that the two genera of Firmicutes could potentially serve as predictive biomarker of HCC, since in wo-HCC was decreased by 5-fold and in HCC was increased by 3-fold.
Several members of the gut microbiome were also found significantly decreased in HCC cases. For instance, the genus Fusobacterium was found 5-fold decreased in HCC versus wo-HCC. Elevated levels of Fusobacterium were found associated with tumorigenesis process in the gut and a proinflammatory microenvironment 32 .
However, we found decreased levels in the HCC cases; showing that a specific micriobiome related cancer might be found in different tumors.
Bacteroides and Prevotella are major genus of the Bacteriodetes phylum present in the gut, but they are mutually excluded in the dominance as they are clearly competitors for the niche. Prevotella are usually found in non-western diets such as plant-rich fiber diets. However, prevotella was also linked to chronic inflammation processes. In our study, the ratio bacteriodes/prevotella was increased in HCC cases due to the significant decrease in the genus prevotella and no significant changes in the genus bacteroides. In fact, prevotella was decreased by at least 3-fold in HCC cases. This observation is under further investigation by our group.
Finally, the key question is whether these findings observed in this case-control study, will be repeated in a cohort study evaluating microbiome changes over time. Our group is in a second phase of research including a longitudinal microbiome measurement. This will allow us to clarify whether these preliminary observations explain a novel pathophysiological mechanism in the generation of HCC.
In our study, changes in abundance in HCC patients correlated with an increase in the predicted metabolism of NOD-like receptor (NLRs) signaling pathway. However, we are aware that abundant molecular functions are not necessarily provided by abundant species, highlighting the importance of a functional analysis for a community understanding 14 . NOD-like receptors are intracellular sensor with central roles in innate and adaptive immunity. Whereas the membrane-bound Toll-like receptors (TLRs) survey the extracellular milieu, NLRs have emerged as key sensors of infection and stress in intracellular compartments 14 . These molecules act as sensors of microbial fragments inside the human cytosol of infected cells. Once activated, NLRs recruit NF-κβ and facilitate the production of interferon type I. These NLRs can regulate several aspects of the immune response.
In this sense, it has been previously observed that in cirrhosis, a "leaky" gut accounting for an impaired intestinal barrier function and bacterial overgrowth leads to development of main clinical events in cirrhosis. These bacterial products induce inflammation through activation of TLR and NLRs in the liver, inducing a inflammatory environment of cancer development 12, 13 .
We recognize that this study has limitations including first, that in case-control studies, several predictive factors might be biased. However, a strict revision of potentially selection and information bias was done. Second, the limited number of included patients is a main caveat. However, these preliminary observations should be evaluated in a longitudinal assessment of gut microbiota in cirrhotic patients with higher risk of HCC development.
In conclusion, we found several different genera and families in the gut microbiota that were decreased or elevated in HCC cases versus controls (wo-HCC). Patients with HCC had lower quantities of genus Prevotella, Fusobacterium and family Leuconostocaccaceae among others and an elevated proportion of genus Bifidobacterium, Eggerthella, Haemophilus, family Erysipelotrichaceae and phylum Tenericutes when compared to controls without HCC. This pattern was associated with inflammatory pathways. It would be interesting to explore the utility of these members as biomarkers of disease progression in a larger cohort study and eventually, in an intervention prevention trial. 
HCC, non-HCC patients and healthy individuals (Panels A-C).
Note: A bacteriodes/prevotella ratio was greater in HCC than in non-HCC controls and healthy controls. 
